We consider that the use of pregabalin in the presented two cases may be the causal effect of the CSCR diagnosis, as pathophysiology of CSCR is in parallel with the edema-related adverse effects of pregabalin
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Pregabalin is commonly used for the treatment of neuropathic pain and is attributed to adverse effects of peripheral vasodilation and peripheral edema.
📊
Key Findings & Data:Central serous chorioretinopathy (CSCR) is characterized by choroidal fluid leaks from choroidal vessels under the retina, causing focal retinal detachment with macular vision loss.
💡
Conclusion & Impact:We consider that the use of pregabalin in the presented two cases may be the causal effect of the CSCR diagnosis, as pathophysiology of CSCR is in parallel with the edema-related adverse effects of pregabalin
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Pregabalin is commonly used for the treatment of neuropathic pain and is attributed to adverse effects of peripheral vasodilation and peripheral edema. Central serous chorioretinopathy (CSCR) is characterized by choroidal fluid leaks from choroidal vessels under the retina, causing focal retinal detachment with macular vision loss. Herein, we report two cases admitted to our clinic with vision loss while under pregabalin treatment. Upon eye examination, both patients were diagnosed with acute CSCR. Pregabalin treatment was discontinued upon the diagnosis of CSCR. We consider that the use of pregabalin in the presented two cases may be the causal effect of the CSCR diagnosis, as pathophysiology of CSCR is in parallel with the edema-related adverse effects of pregabalin
🔖
Cite This Article
DOĞAN, Y. E., OKTAY, K. N. K., ÖZKURT, Y. B., AKTAŞ, L. (2021). Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports. Turkish journal of physical medicine and rehabilitation, Cilt: 67 - Sayı: 4, 530–533. https://ajindex.com/articles/408570
Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol 2016;94:321-5
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82-118
Wustmann T, Piro J, Gutmann P. Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry 2009;42:75-6
Gallagher R, Apostle N. Peripheral edema with pregabalin. CMAJ 2013;185:E506
Guzelkucuk U, Duman I, Yılmaz B, Tan AK. Reversible post-pregabalin peripheral edema in a spinal cord injury patient. Spinal Cord 2012;50:472-3
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
Lyrica® (pregabalin) Prescribing Information. Pfizer Pharmaceuticals LLC. New York, NY 10017. June 2012. Avaelable at: http://labeling.pfizer.com/showlabeling. aspx?id=561. [Accessed: September 14, 2019] 8. Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf 2012;11:487-502
Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010;11:85
Page RL 2nd, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown) 2008;9:922-5
Tanyıldız B, Kandemir B, Mangan MS, Tangılntız A, Göktaş E, Şimşek Ş. Bilateral Serous Macular Detachment After Attempted Suicide with Pregabalin. Turk J Ophthalmol 2018;48:254-7
Mazumdar S, Tripathy K, Sarma B, Agarwal N. Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake. Eur J Ophthalmol 2019;29:NP21-NP24
Ekinci AS, Ciftci S, Cavus B, Aydogdu I. Could pregabalin cause oculomotor symptoms in lower dose? A case with down beat nystagmus as a side effect. Acta Neurol Belg 2017;117:777-8
Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens 2011;29:1270-80
Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretin